查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957532

2026年全球腫瘤輔助治療市場報告

Oncology Adjuvants Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，腫瘤輔助治療市場經歷了顯著成長。預計該市場規模將從2025年的17.3億美元成長至2026年的18.7億美元，複合年成長率（CAGR）為8.2%。過去幾年成長要素包括腫瘤輔助治療藥物供應有限、對化療和放射線治療的高度依賴、全球癌症發病率上升、輔助性治療臨床研究的進展以及腫瘤科醫生對輔助治療益處的認知不斷提高。

預計未來幾年腫瘤輔助治療市場將維持強勁成長，2030年將達到25.4億美元，複合年成長率（CAGR）為7.9%。預測期內的成長要素包括新型免疫療法輔助藥物的研發、標靶治療方案的拓展、聯合治療的日益普及、精準醫療和基因組分析的整合，以及對腫瘤研究和臨床試驗投入的增加。預測期內的主要趨勢包括免疫療法和標靶治療輔助藥物的廣泛應用、個人化癌症治療方案的進一步整合、口服和皮下給藥途徑的拓展、多學科癌症治療方法的興起，以及對改善患者預後和減少治療副作用的重視。

日益成長的個人化醫療需求預計將推動輔助腫瘤治療市場的成長。個人化醫療是一種利用個人基因譜和生活方式因素來客製化治療和照護的醫療框架。其興起得益於基因和分子分析技術的進步，這些技術能夠根據個體的生物學特徵量身定做治療方案，從而獲得更好的療效並減少副作用。輔助腫瘤治療透過基於患者的基因資訊和腫瘤特徵進行個人化輔助癌症治療，從而支持個人化醫療，有效清除殘留癌細胞並抑制過度毒性。例如，根據美國個人化醫療聯盟（PMC）2024年2月發布的報告，美國食品藥物管理局（FDA）在2023年核准了16種針對罕見疾病患者的新型個人化療法，是2022年批准的6種療法的兩倍。因此，對個人化醫療日益成長的需求正在推動輔助性治療市場的發展。

腫瘤輔助治療市場的主要企業正透過免疫查核點抑制劑輔助性治療等先進方法進行創新。該療法旨在透過激活人體自身對抗殘留癌細胞的防禦機制，增強術後治療效果並提高患者存活率。免疫查核點抑制劑輔助性治療使用能夠抑制PD-1、PD-L1和CTLA-4等通常抑制免疫活性的蛋白質的藥物。例如，2023年1月，美國大型製藥公司默克推出了獲得FDA核准的輔助性治療Keytruda（Pembrolizumab）。此藥物用於接受鉑類化療後，IB期（T2a≥4 cm）、II期或IIIA期非小細胞肺癌（NSCLC）患者的治療。 Keytruda（Pembrolizumab）透過靶向PD-1受體，實現精準的免疫查核點抑制，從而重新激活免疫系統識別和清除癌細胞的能力。 Keytruda是一種強效的非小細胞肺癌術後及化療後化療方案，可顯著降低復發風險並延長存活期。此外，Keytruda利用患者特異性的免疫動力學，推動個人化癌症治療的發展，鞏固了其在現代免疫腫瘤學中的地位。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球腫瘤輔助治療市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 數位化、雲端運算、巨量資料、網路安全
    • 人工智慧（AI）和自主人工智慧
    • 工業4.0和智慧製造
    • 物聯網、智慧基礎設施、互聯生態系統
  • 主要趨勢
    • 免疫療法和標靶治療輔助劑的使用增加
    • 個人化癌症治療方案的整合正在取得進展。
    • 擴大口服和皮下給藥途徑
    • 多方面癌症治療方法的發展
    • 致力於改善患者治療效果並減少治療副作用。

第5章 終端用戶產業市場分析

  • 癌症研究機構
  • 癌症專科醫院
  • 專科腫瘤診所
  • 學術和研究機構
  • 臨床試驗中心

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球腫瘤輔助治療市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球腫瘤輔助治療市場規模、對比及成長率分析
  • 全球腫瘤輔助治療市場表現：規模與成長，2020-2025年
  • 全球腫瘤輔助治療市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按補充劑類型
  • 化療輔助藥物、放射線治療輔助藥物、免疫療法輔助藥物、荷爾蒙療法輔助藥物、標靶治療輔助藥物
  • 透過行政途徑
  • 口服、靜脈注射、皮下注射、局部、肌肉注射
  • 指示
  • 乳癌、膠質母細胞瘤、肺癌、大腸直腸癌、卵巢癌、肉瘤、攝護腺癌及其他適應症
  • 最終用戶
  • 癌症研究所，癌症專科醫院
  • 依類型細分：化療輔助藥物
  • 烷化劑、抗代謝物、蔥環類抗生素、植物生物鹼、拓樸異構酶抑制劑、鉑化合物等。
  • 按類型細分：輔助性治療
  • 放射增敏劑、放射防護劑、乏氧細胞增敏劑、去氧核糖核酸(DNA) 修復抑制劑、免疫調節劑與輻射合併使用
  • 按類型細分：免疫療法佐劑
  • 查核點抑制劑、細胞激素、癌症疫苗、過繼性細胞移植、免疫調節劑
  • 按類型細分：荷爾蒙輔助性治療
  • 選擇性雌激素受體調節、Aromatase抑制劑、促性腺激素分泌釋放激素促效劑或拮抗劑、雄性激素受體抑制劑、雌激素受體穩壓器
  • 按類型細分：標靶治療的輔助治療
  • 蛋白酪氨酸激酶抑制劑（TKIs）、蛋白酶體抑制劑、聚（ADP-核糖）聚合酵素（PARP）抑制劑、mTOR抑制劑、v-Raf小鼠肉瘤病毒癌基因同源物B（BRAF）或絲裂原活化蛋白激酶激酶（MEK）抑制劑、血管內皮生長因子（VEGF）抑制劑

第10章 區域與國別分析

  • 全球腫瘤輔助治療市場：依地區分類，歷史資料及預測（2020-2025年、2025-2030年、2035年）
  • 全球腫瘤輔助治療市場：依國家分類，歷史資料及預測，2020-2025年、2025-2030年、2035年

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 腫瘤輔助治療市場：競爭格局及市場佔有率（2024年）
  • 腫瘤輔助治療市場：公司估值矩陣
  • 腫瘤輔助治療市場：公司概況
    • Pfizer Inc.
    • Johnson And Johnson
    • Roche Holding AG
    • Merck And Co. Inc.
    • Bayer AG

第37章 其他大型企業和創新企業

  • Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年腫瘤輔助治療市場：提供新機會的國家
  • 2030年腫瘤輔助治療市場：蘊藏新機會的細分市場
  • 2030年腫瘤輔助治療市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH4MOADJ01_G26Q1

Oncology adjuvants are substances or therapies administered alongside primary cancer treatments to enhance therapeutic effectiveness, reduce side effects, and improve patient outcomes. These adjuvants work by boosting the immune response, mitigating tumor resistance, or aiding in symptom management, thereby supporting a more comprehensive and personalized approach to cancer care.

The main types of oncology adjuvants include chemotherapy adjuvants, radiation adjuvants, immunotherapy adjuvants, hormonal adjuvants, and targeted therapy adjuvants. Chemotherapy adjuvants consist of drugs or compounds used in conjunction with primary chemotherapy to increase efficacy, reduce adverse effects, or enhance the patient's response to treatment. Oncology adjuvants are administered through various routes, including oral, intravenous, subcutaneous, topical, and intramuscular delivery. They are applied across multiple indications, such as breast cancer, glioblastoma, lung cancer, colorectal cancer, ovarian cancer, sarcoma, and prostate cancer, and serve a range of end users, including cancer hospitals, oncology clinics, and research institutions focused on cancer therapeutics.

Tariffs have impacted the oncology adjuvants market by increasing costs of imported biologics, chemotherapy adjuvants, and advanced immunotherapy agents. Segments such as immunotherapy adjuvants and targeted therapy adjuvants are most affected, with North America and Europe relying heavily on imports from Asia-Pacific regions like China and India. This has increased treatment costs and caused potential delays in therapy availability. On the positive side, tariffs have encouraged local production, research, and development of cost-optimized adjuvant therapies.

The oncology adjuvants market research report is one of a series of new reports from The Business Research Company that provides oncology adjuvants market statistics, including oncology adjuvants industry global market size, regional shares, competitors with a oncology adjuvants market share, detailed oncology adjuvants market segments, market trends and opportunities, and any further data you may need to thrive in the oncology adjuvants industry. This oncology adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology adjuvants market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.87 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to limited availability of oncology adjuvants, reliance on chemotherapy and radiation as primary treatments, growing cancer incidence globally, increasing clinical research on adjuvant therapies, awareness of adjuvant benefits among oncologists.

The oncology adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of novel immunotherapy adjuvants, expansion of targeted therapy options, increasing adoption of combination therapy approaches, integration of precision medicine and genomic profiling, rising investment in oncology research and clinical trials. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapy adjuvants, increased integration of personalized cancer treatment plans, expansion of oral and subcutaneous administration routes, growth in multi-modal cancer treatment approaches, focus on enhancing patient outcomes and reducing therapy side effects.

The growing need for personalized medicine is set to boost the oncology adjuvants market ahead. Personalized medicine is a healthcare framework that leverages a person's genetic profile and lifestyle factors to customize treatments and care. Its rise stems from strides in genetic and molecular analysis, facilitating therapies matched to an individual's biology for better results and fewer side effects. Oncology adjuvants support personalized medicine by enabling tailored supplemental cancer therapies based on a patient's genetics and tumor traits, effectively hitting leftover cancer cells while curbing excess toxicity. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US organization, reported that the FDA approved 16 novel personalized therapies for rare disease patients in 2023, doubling from 6 in 2022. Thus, the rising demand for personalized medicine is fueling the oncology adjuvants market.

Leading companies in the oncology adjuvants market are innovating with advanced approaches like immune checkpoint inhibitor adjuvant therapy to amplify post-surgery outcomes and boost patient survival by activating the body's defenses against lingering tumor cells. Immune checkpoint inhibitor adjuvant therapy involves medications that disrupt proteins like PD-1, PD-L1, or CTLA-4, which typically restrain immune activity. For instance, in January 2023, Merck & Co., Inc., a US pharmaceutical leader, introduced KEYTRUDA (pembrolizumab) as an FDA-approved adjuvant regimen. It comes after surgery and platinum chemotherapy for Stage IB (T2a >=4 cm), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) delivers precise immune checkpoint blockade by targeting the PD-1 receptor, reawakening the immune system's capacity to recognize and eliminate cancer cells. It offers a potent post-surgical and chemo option for NSCLC patients, slashing recurrence risks and extending survival. Moreover, KEYTRUDA advances individualized oncology by tapping into patient-specific immune dynamics, cementing its role in contemporary immuno-oncology.

In January 2024, Transgene S.A., a France-based healthcare tech firm, teamed up with NEC Corporation to pioneer robotic-assisted medical tools. Through this alliance, Transgene and NEC intend to sharpen procedure precision, streamline operations, and elevate patient results by merging Transgene's therapy expertise with NEC's AI, 5G, and imaging prowess-enhancing workflows, aiding instant clinical choices, and expanding access to sophisticated care. NEC Corporation is a Japan-based tech giant excelling in IT, communications, and AI-powered imaging for healthcare and business uses.

Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

North America was the largest region in the oncology adjuvants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology adjuvants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology adjuvants market consists of revenues earned by entities by providing services such as treatment enhancement, side effect reduction, tumor resistance prevention, and personalized therapy optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology adjuvants market also includes sales of nutritional adjuvants, gene therapy adjuvants, oncolytic virus adjuvants, and hyperthermia adjuvants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Adjuvants Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oncology adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology adjuvants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology adjuvants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type Of Adjuvant: Chemotherapy Adjuvants; Radiation Adjuvants; Immunotherapy Adjuvants; Hormonal Adjuvants; Targeted Therapy Adjuvants
  • 2) By Administration Route: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
  • 3) By Indication: Breast Cancer; Glioblastoma; Lung Cancer; Colorectal Cancer; Ovarian Cancer; Sarcoma; Prostate Cancer; Other Indications
  • 4) By End User: Cancer Research Institute; Cancer Hospitals
  • Subsegments:
  • 1) By Chemotherapy Adjuvants: Alkylating Agents; Antimetabolites; Anthracyclines; Plant Alkaloids; Topoisomerase Inhibitors; Platinum-Based Compounds; Others
  • 2) By Radiation Adjuvants: Radiosensitizers; Radioprotectors; Hypoxic Cell Sensitizers; Deoxyribonucleic Acid (DNA) Repair Inhibitors; Immune Modulating Agents Combined With Radiation
  • 3) By Immunotherapy Adjuvants: Checkpoint Inhibitors; Cytokines; Cancer Vaccines; Adoptive Cell Transfer; Immune Modulating Agents
  • 4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators; Aromatase Inhibitors; Gonadotropin-Releasing Hormone Agonists Or Antagonists; Androgen Receptor Inhibitors; Estrogen Receptor Downregulators
  • 5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Poly (ADP-Ribose) Polymerase (PARP) Inhibitors; mTOR Inhibitors; v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Eli Lilly And Company; Amgen Inc.; Regeneron Pharmaceuticals; Daiichi Sankyo Company Limited; Ipsen S.A.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Croda International Plc; Dynavax Technologies Corporation; Agenus Inc.; Elicio Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Oncology Adjuvants Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Oncology Adjuvants Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Oncology Adjuvants Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Oncology Adjuvants Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Artificial Intelligence & Autonomous Intelligence
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Immunotherapy And Targeted Therapy Adjuvants
    • 4.2.2 Increased Integration Of Personalized Cancer Treatment Plans
    • 4.2.3 Expansion Of Oral And Subcutaneous Administration Routes
    • 4.2.4 Growth In Multi-Modal Cancer Treatment Approaches
    • 4.2.5 Focus On Enhancing Patient Outcomes And Reducing Therapy Side Effects

5. Oncology Adjuvants Market Analysis Of End Use Industries

  • 5.1 Cancer Research Institutes
  • 5.2 Cancer Hospitals
  • 5.3 Specialty Oncology Clinics
  • 5.4 Academic And Research Laboratories
  • 5.5 Clinical Trial Centers

6. Oncology Adjuvants Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oncology Adjuvants Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Oncology Adjuvants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Oncology Adjuvants Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Oncology Adjuvants Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Oncology Adjuvants Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oncology Adjuvants Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oncology Adjuvants Market Segmentation

  • 9.1. Global Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants
  • 9.2. Global Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oral, Intravenous, Subcutaneous, Topical, Intramuscular
  • 9.3. Global Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications
  • 9.4. Global Oncology Adjuvants Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cancer Research Institute, Cancer Hospitals
  • 9.5. Global Oncology Adjuvants Market, Sub-Segmentation Of Chemotherapy Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others
  • 9.6. Global Oncology Adjuvants Market, Sub-Segmentation Of Radiation Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation
  • 9.7. Global Oncology Adjuvants Market, Sub-Segmentation Of Immunotherapy Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents
  • 9.8. Global Oncology Adjuvants Market, Sub-Segmentation Of Hormonal Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators
  • 9.9. Global Oncology Adjuvants Market, Sub-Segmentation Of Targeted Therapy Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors

10. Oncology Adjuvants Market Regional And Country Analysis

  • 10.1. Global Oncology Adjuvants Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Oncology Adjuvants Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oncology Adjuvants Market

  • 11.1. Asia-Pacific Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oncology Adjuvants Market

  • 12.1. China Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oncology Adjuvants Market

  • 13.1. India Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oncology Adjuvants Market

  • 14.1. Japan Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oncology Adjuvants Market

  • 15.1. Australia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oncology Adjuvants Market

  • 16.1. Indonesia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oncology Adjuvants Market

  • 17.1. South Korea Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oncology Adjuvants Market

  • 18.1. Taiwan Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oncology Adjuvants Market

  • 19.1. South East Asia Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oncology Adjuvants Market

  • 20.1. Western Europe Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oncology Adjuvants Market

  • 21.1. UK Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oncology Adjuvants Market

  • 22.1. Germany Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oncology Adjuvants Market

  • 23.1. France Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oncology Adjuvants Market

  • 24.1. Italy Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oncology Adjuvants Market

  • 25.1. Spain Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oncology Adjuvants Market

  • 26.1. Eastern Europe Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oncology Adjuvants Market

  • 27.1. Russia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oncology Adjuvants Market

  • 28.1. North America Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oncology Adjuvants Market

  • 29.1. USA Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oncology Adjuvants Market

  • 30.1. Canada Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oncology Adjuvants Market

  • 31.1. South America Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oncology Adjuvants Market

  • 32.1. Brazil Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oncology Adjuvants Market

  • 33.1. Middle East Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oncology Adjuvants Market

  • 34.1. Africa Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oncology Adjuvants Market Regulatory and Investment Landscape

36. Oncology Adjuvants Market Competitive Landscape And Company Profiles

  • 36.1. Oncology Adjuvants Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Oncology Adjuvants Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Oncology Adjuvants Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Oncology Adjuvants Market Other Major And Innovative Companies

  • Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

38. Global Oncology Adjuvants Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oncology Adjuvants Market

40. Oncology Adjuvants Market High Potential Countries, Segments and Strategies

  • 40.1 Oncology Adjuvants Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Oncology Adjuvants Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Oncology Adjuvants Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer